FIGURE 5.

The novel RIPK2 inhibitor OD36 reduces cellular infiltration in an in vivo MDP-induced peritonitis model. A, mice were administered vehicle, Gefitinib or the novel RIPK2 inhibitor OD36 at 6.25 mg/kg intraperitoneal 30 min before intraperitoneal delivery of 150 μg of MDP for an additional 4 h. Cellular differentials of peritoneal lavages from individual mice are shown. The data are represented as a bar graph in B for clearer presentation of statistical analysis. Both Gefitinib and OD36 show reduction of the MDP-induced recruitment of WBC, particularly that of neutrophils and lymphocytes (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001). C, RNA was extracted from cellular infiltrate obtained from each experimental group and qRT-PCR was performed. Expression of both genetic RIPK2 activation markers as well as cytokines and chemokines were reduced in the Gefitinib-treated animals but more so in the animals receiving the same dose of OD36.